BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity via positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood transcriptome liquid biopsy (WBT lbx) for which we recently reported feasibility to mirror tumor characteristics and response to particle irradiation in recurrent HGG (rHGG).Methods18F-FET-PET data from n = 43 patients with primary glioblastoma (pGBM) and n = 33 patients with rHGG were assessed. pGBM patients were irradiated with photons and sequential proton/carbon boost, and rHGG patients were treated with carbon re-irradiation (CIR). WBT (Illumina ...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
The use of 18F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active...
Introduction Glioblastoma is the most common aggressive primary central nervous system cancer in adu...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
Background: Selective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (...
Selective uptake of (18)F-fluoro-ethyl-tyrosine ($^{18}$F-FET) is used in high-grade glioma (HGG) to...
[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma W...
OnlinePublThe O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Austral...
OBJECTIVE The aim of this prospective longitudinal study was to identify static and dynamic O-(2-[(...
The PET tracer O-(2-[18F]Fluoroethyl)-l-tyrosine (FET) has been shown to be valuable for different r...
Item does not contain fulltext3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical...
Introduction: Today, magnetic resonance imaging (MRI) is the standard method for monitoring patients...
The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-br...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
The use of 18F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active...
Introduction Glioblastoma is the most common aggressive primary central nervous system cancer in adu...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
BackgroundSelective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (HG...
Background: Selective uptake of (18)F-fluoro-ethyl-tyrosine (18F-FET) is used in high-grade glioma (...
Selective uptake of (18)F-fluoro-ethyl-tyrosine ($^{18}$F-FET) is used in high-grade glioma (HGG) to...
[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma W...
OnlinePublThe O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Austral...
OBJECTIVE The aim of this prospective longitudinal study was to identify static and dynamic O-(2-[(...
The PET tracer O-(2-[18F]Fluoroethyl)-l-tyrosine (FET) has been shown to be valuable for different r...
Item does not contain fulltext3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a radiopharmaceutical...
Introduction: Today, magnetic resonance imaging (MRI) is the standard method for monitoring patients...
The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-br...
The aim of this study was to assess the clinical value of O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-...
The use of 18F-FDG PET for brain tumors has been shown to be accurate in identifying areas of active...
Introduction Glioblastoma is the most common aggressive primary central nervous system cancer in adu...